Kardigan (KARD) Corporate presentation summary

Strategic vision and leadership

• Focused on precision cardiovascular medicine, leveraging biology, data, and analytics to address unmet needs in heart health.

• Led by an experienced team with backgrounds from Myokardia, Sanofi, Genentech, and other major biopharma companies.

• Supported by blue-chip healthcare investors and a capital-efficient business model.

Market opportunity and unmet need

• Cardiovascular disease (CVD) causes 30% of annual U.S. deaths and is expected to cost $1.8T by 2050.

• Only 7% of phase 3 clinical trials and 5% of drugs in development target CVD, highlighting a large, underserved market.

Late-stage clinical programs

• Three late-stage programs: Danicamtiv for genetic dilated cardiomyopathy (DCM), Ataciguat for moderate calcific aortic valve stenosis (CAVS), and Tonlamarsen for acute severe hypertension (ASH).

• Each program targets the root cause of disease in well-defined patient populations, with upcoming phase 2b/3 data readouts expected in 1H 2027.